[Ovulation induction with human menopausal gonadotropins in hypothalamic-hypophyseal disfunction].
This is a report on the institutional experience of the use of Human Menopausal Gonadotropins (HMG) in anovulatory women diagnosed as hypothalamic-hypophysiary dysfunction of Group II of WHO with previous failure to chlomifen citrate therapy. In a period of three years 180 patients were gathered with 420 cycle of treatment, obtaining ovulation in 340 cycles (81%). The ovarian hyperstimulation syndrome (OHS) was present in 15 cases (3.5%). There were 115 pregnancies that correspond to 33.8% of oculatory cycles and to 63.8% of the amount of patients. Multiple pregnancy incidence was 10.4%, and the gestational loses rate was 26%; these results are similar to what has been reported in literature. It is concluded that this medication is a good option of treatment for this type of patients, provided that there are the necessary means to expert and adequate surveillance.
Ibarra Chavarria
V
V
Mota Gonzalez
M
M
Carballar Lopez
G
G
Espinosa de los Monteros
A
A
Karchmer
S
S
D000328:Adult; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects / Q000503:physiopathology*; D008596:Menotropins / Q000008:administration & dosage* / Q000494:pharmacology; D016471:Ovarian Hyperstimulation Syndrome / Q000139:chemically induced*; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D016896:Treatment Outcome; D014944:World Health Organization
D008596:Menotropins
Inducción de ovulación con gonadotropinas menopáusicas humanas en disfunción hipotálamo-hipofisiaria.